Tonka
Well-known member
http://www.elcolombiano.com/BancoCo...de_agresividad_en_leucemia.asp?CodSeccion=193
Spanish to English translation
Identify genes of aggressiveness in leukemia
In a research conducted in Salamanca, Spain, we identified genes that distinguish aggressive leukemias. A breakthrough for medicine that will define the diagnosis of the disease and its respective treatment.
Efe | Salamanca, Spain | Posted on January 30, 2011
Spanish researcher Carlos Manuel Santamar?a, University of Salamanca, has identified new tumor markers or genes that distinguish aggressive leukemia in a slower development, explained to reporters the scientist himself.
Research, reflected in doctoral thesis entitled Study of molecular markers for prognosis and monitoring of minimal residual disease in patients with acute myelogenous leukemia has won the prize Moraza Doctor Foundation of the University of Salamanca, worth 3,530 euros (about $ 4,836.)
Directed by Dr. Marcos Gonz?lez D?az, the thesis advances in identifying genes that distinguish leukemia in terms of their aggressiveness and detect possible warning signs to predict future relapse.
Santamar?a advances in the identification of new molecular markers or genes that allow the one hand, "differentiate those leukemias a slower evolution of those with very aggressive behavior," said the scientist to the media.
In addition, we can "to more accurately track the evolution of tumor cells that remain in the body of the patient after chemotherapy," he added.
The study
Santamaria's research focuses on minimal residual disease, that is, possible relapses of acute myelogenous leukemia (AML), a type of cancer affecting the blood, with a higher incidence in the adult population and which is a highly heterogeneous disease.
This monitoring, as Santamaria, "would determine the levels of markers that can be considered warning signals to predict a future relapse of the patient."
In particular his doctoral thesis focuses on leukemia with normal karyotype, ie in those patients without alterations in their chromosomes and thus lack of markers to determine whether a disease is good or bad prognosis.
Research Foundation award for Moraza Doctor "provides exactly five new markers that can be stratified into risk groups for these patients and discover the critical levels or warning signs in another subtype of leukemia, M3, with good prognosis but requires monitoring comprehensive patient. "
Since this cancer includes different subtypes with different prognoses, ranging from a 5-year survival rate exceeding 80 percent to some very unfavorable, Santamaria said that "the better define the diagnosis and classification of leukemia, the better we can achieve more specific therapeutic approach to the patient, according to the biological characteristics of their disease. "
Spanish to English translation
Identify genes of aggressiveness in leukemia
In a research conducted in Salamanca, Spain, we identified genes that distinguish aggressive leukemias. A breakthrough for medicine that will define the diagnosis of the disease and its respective treatment.
Efe | Salamanca, Spain | Posted on January 30, 2011
Spanish researcher Carlos Manuel Santamar?a, University of Salamanca, has identified new tumor markers or genes that distinguish aggressive leukemia in a slower development, explained to reporters the scientist himself.
Research, reflected in doctoral thesis entitled Study of molecular markers for prognosis and monitoring of minimal residual disease in patients with acute myelogenous leukemia has won the prize Moraza Doctor Foundation of the University of Salamanca, worth 3,530 euros (about $ 4,836.)
Directed by Dr. Marcos Gonz?lez D?az, the thesis advances in identifying genes that distinguish leukemia in terms of their aggressiveness and detect possible warning signs to predict future relapse.
Santamar?a advances in the identification of new molecular markers or genes that allow the one hand, "differentiate those leukemias a slower evolution of those with very aggressive behavior," said the scientist to the media.
In addition, we can "to more accurately track the evolution of tumor cells that remain in the body of the patient after chemotherapy," he added.
The study
Santamaria's research focuses on minimal residual disease, that is, possible relapses of acute myelogenous leukemia (AML), a type of cancer affecting the blood, with a higher incidence in the adult population and which is a highly heterogeneous disease.
This monitoring, as Santamaria, "would determine the levels of markers that can be considered warning signals to predict a future relapse of the patient."
In particular his doctoral thesis focuses on leukemia with normal karyotype, ie in those patients without alterations in their chromosomes and thus lack of markers to determine whether a disease is good or bad prognosis.
Research Foundation award for Moraza Doctor "provides exactly five new markers that can be stratified into risk groups for these patients and discover the critical levels or warning signs in another subtype of leukemia, M3, with good prognosis but requires monitoring comprehensive patient. "
Since this cancer includes different subtypes with different prognoses, ranging from a 5-year survival rate exceeding 80 percent to some very unfavorable, Santamaria said that "the better define the diagnosis and classification of leukemia, the better we can achieve more specific therapeutic approach to the patient, according to the biological characteristics of their disease. "